Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Mar 7 3:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: FNS who wrote (773)	8/25/1998 11:28:00 AM
From: Hong-Lee Yu	Read Replies (2) of 965

Remicade (aka Avakine) will be very profitable. Most SG & A expenses related to Remicade should be already shown up in Q2. The Co stated in 1997 annual reports that they need no more than 50 sales force to cover 90% of market in USA. In addition, they will get 60% profit from SGP for Remicade sales in non-USA market. If they can have 100M revenues in Remicade (USA) in 1999 as projected, at least 50M will go to the buttom line.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next